These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31352795)

  • 1. Donor Simvastatin Treatment in Heart Transplantation.
    Nykänen AI; Holmström EJ; Tuuminen R; Krebs R; Dhaygude K; Kankainen M; Jokinen JJ; Lommi J; Helanterä I; Räisänen-Sokolowski A; Syrjälä SO; Lemström KB
    Circulation; 2019 Aug; 140(8):627-640. PubMed ID: 31352795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor simvastatin treatment abolishes rat cardiac allograft ischemia/reperfusion injury and chronic rejection through microvascular protection.
    Tuuminen R; Syrjälä S; Krebs R; Keränen MA; Koli K; Abo-Ramadan U; Neuvonen PJ; Tikkanen JM; Nykänen AI; Lemström KB
    Circulation; 2011 Sep; 124(10):1138-50. PubMed ID: 21844074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined donor simvastatin and methylprednisolone treatment prevents ischemia-reperfusion injury in rat cardiac allografts through vasculoprotection and immunomodulation.
    Tuuminen R; Syrjälä S; Krebs R; Arnaudova R; Rouvinen E; Nykänen AI; Lemström KB
    Transplantation; 2013 May; 95(9):1084-91. PubMed ID: 23466635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive perioperative simvastatin treatment protects from chronic kidney allograft injury.
    Palin NK; Savikko J; Rintala JM; Koskinen PK
    Am J Nephrol; 2015; 41(4-5):383-91. PubMed ID: 26111494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin pretreatment reduces caspase-9 and RIPK1 protein activity in rat cardiac allograft ischemia-reperfusion.
    Tuuminen R; Holmström E; Raissadati A; Saharinen P; Rouvinen E; Krebs R; Lemström KB
    Transpl Immunol; 2016 Jul; 37():40-45. PubMed ID: 27155462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts.
    Atkinson C; Floerchinger B; Qiao F; Casey S; Williamson T; Moseley E; Stoica S; Goddard M; Ge X; Tullius SG; Tomlinson S
    Circulation; 2013 Mar; 127(12):1290-9. PubMed ID: 23443736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor plasma VEGF-A as a biomarker for myocardial injury and primary graft dysfunction after heart transplantation.
    Holmström EJ; Syrjälä SO; Dhaygude K; Tuuminen R; Krebs R; Lommi J; Nykänen A; Lemström KB
    J Heart Lung Transplant; 2024 Oct; 43(10):1677-1690. PubMed ID: 38897424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor simvastatin treatment and cardiac allograft ischemia/reperfusion injury.
    Nykänen AI; Tuuminen R; Lemström KB
    Trends Cardiovasc Med; 2013 Apr; 23(3):85-90. PubMed ID: 23295079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin attenuates cardiac isograft ischemia-reperfusion injury by down-regulating CC chemokine receptor-2 expression.
    Yin R; Zhu J; Wang Z; Huang H; Qian J; Li Z; Jing H
    J Thorac Cardiovasc Surg; 2007 Sep; 134(3):780-8. PubMed ID: 17723833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does duration of donor brain injury affect outcome after orthotopic pediatric heart transplantation?
    Odim J; Laks H; Banerji A; Mukherjee K; Vincent C; Murphy C; Burch C; Gjertson D
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):187-93. PubMed ID: 15999061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum concentrations of cardiac troponin T in acute allograft rejection after human heart transplantation.
    Dengler TJ; Zimmermann R; Braun K; Müller-Bardorff M; Zehelein J; Sack FU; Schnabel PA; Kübler W; Katus HA
    J Am Coll Cardiol; 1998 Aug; 32(2):405-12. PubMed ID: 9708468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival.
    Mehra MR; Uber PA; Vivekananthan K; Solis S; Scott RL; Park MH; Milani RV; Lavie CJ
    J Am Coll Cardiol; 2002 Nov; 40(9):1609-14. PubMed ID: 12427413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers and Donor Selection in Heart Transplantation.
    Vorlat A; De Hous N; Vervaecke AJ; Vermeulen T; Van Craenenbroeck E; Heidbuchel H; Rodrigus I; Van Donink W; Ancion A; Van Cleemput J; Van Hoof VO; Claeys MJ
    Transplant Proc; 2019; 51(6):1673-1678. PubMed ID: 31307770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival, graft function, and incidence of allograft vasculopathy in heart transplant patients receiving adverse risk profile donor hearts.
    Berg K; Clemmensen TS; Tram EM; Koefoed-Nielsen P; Ilkjaer LB; Poulsen SH; Eiskjaer H
    Clin Transplant; 2018 Aug; 32(8):e13343. PubMed ID: 29974979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor cardiac troponin T: a marker to predict heart transplant rejection.
    Vijay P; Scavo VA; Morelock RJ; Sharp TG; Brown JW
    Ann Thorac Surg; 1998 Dec; 66(6):1934-9. PubMed ID: 9930472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year survival rates for all consecutive heart-only and lung-only transplants performed in Eurotransplant, 1997-1999.
    Smits JM; Vanhaecke J; Haverich A; de Vries E; Smith M; Rutgrink E; Ramsoebhag A; Hop A; Persijn G; Laufer G
    Clin Transpl; 2003; ():89-100. PubMed ID: 15387100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does duration of donor brain injury impact heart transplantation outcomes?
    Kogan A; Ram E; Nachum E; Kassif Y; Lavee J; Peled Y
    Clin Transplant; 2019 Aug; 33(8):e13660. PubMed ID: 31278764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in cardiac transplant recipients using allografts from older donors versus mortality on the transplant waiting list; Implications for donor selection criteria.
    Lietz K; John R; Mancini DM; Edwards NM
    J Am Coll Cardiol; 2004 May; 43(9):1553-61. PubMed ID: 15120811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor tissue-specific exosome profiling enables noninvasive monitoring of acute rejection in mouse allogeneic heart transplantation.
    Habertheuer A; Korutla L; Rostami S; Reddy S; Lal P; Naji A; Vallabhajosyula P
    J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2479-2489. PubMed ID: 29499866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel cardioprotective agent in cardiac transplantation: metformin activation of AMP-activated protein kinase decreases acute ischemia-reperfusion injury and chronic rejection.
    Chin JT; Troke JJ; Kimura N; Itoh S; Wang X; Palmer OP; Robbins RC; Fischbein MP
    Yale J Biol Med; 2011 Dec; 84(4):423-32. PubMed ID: 22180679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.